Bristol-Myers Squibb Company (FRA:BRM)
Germany
· Delayed Price · Currency is EUR | Market Cap | 83.14B |
| Revenue (ttm) | 40.62B |
| Net Income (ttm) | 4.30B |
| Shares Out | n/a |
| EPS (ttm) | 2.12 |
| PE Ratio | 19.34 |
| Forward PE | 7.45 |
| Dividend | 2.24 (5.64%) |
| Ex-Dividend Date | Jul 3, 2025 |
| Volume | 1,761 |
| Average Volume | 2,664 |
| Open | 39.63 |
| Previous Close | 39.82 |
| Day's Range | 39.63 - 40.61 |
| 52-Week Range | 37.66 - 58.79 |
| Beta | n/a |
| RSI | 53.29 |
| Earnings Date | Jul 31, 2025 |
About FRA:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program
Three major pharmaceutical companies — Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Co (NYSE: LLY), and UCB SA (OTC: UCBJY) (OTC: UCBJF) — are suing U.S. Secretary of Health and Human Services (HHS) R...
Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity
Bristol Myers gets priority review for Breyanzi's label expansion
Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) for Breyanzi (lisocabtagene maraleu...
Procurement leaders talk about how AI changing the way they plan, report, and solve problems
Industry experts from Amazon Business, Bristol Myers Squibb, and SMBC Americas discuss AI-driven procurement strategies at BI's virtual event.
Bristol-Myers Squibb: Buy The Weakness
Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks. Read why BMY stock is a buy.
Bristol-Myers Squibb: Declines Have Gone Too Far
Bristol-Myers Squibb's sales are stabilizing, with Q2 net sales up 1% YoY and growth portfolio drugs like Camzyos and Breyanzi showing strong momentum.
Bristol Myers (BMY) Q2 EPS Jumps 36%
Bristol Myers: Dividend Growth, Raised Guidance, And A Double Beat
Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields
Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline
Bristol-Myers Squibb shares snap six-session losing streak
Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)
Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call Transcript
Bristol-Myers Squibb Unusual Options Activity For July 31
Investors with a lot of money to spend have taken a bullish stance on Bristol-Myers Squibb (NYSE: BMY). And retail traders should know. We noticed this today when the trades showed up on publicly ava...
We're lowering our price target on Bristol Myers as two key overhangs persist
Shares were down around 5% on Thursday afternoon despite a beat-and-raise quarter.
Bristol-Myers Squibb Company 2025 Q2 - Results - Earnings Call Presentation
Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations
Bristol Myers Squibb (BMY) Earnings: 2Q25 Key Numbers
Bristol Myers Squibb (NYSE: BMY) reported its second quarter 2025 earnings results today. Total revenues inched up 1% year-over-year to $12.3 billion. Net earnings attributable to BMS were $1.31 billi...
